KC
BBLG

Kepos Capital’s Bone Biologics BBLG Stock Holding History

Kepos Capital’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,042
Closed -$72K – 289
2023
Q2 		$72K Buy
+1,042
New +$273K 0.01% 194

Other funds holding BBLG

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kepos Capital's BBLG Position: Q3 2023 in Review

Kepos Capital sold out of Bone Biologics (BBLG) in Q3 2023, closing a stake of 1,042 shares — an estimated $72K sold.

Kepos Capital first reported a position in BBLG in Q2 2023 and held it in 1 quarter. The position peaked at $72K in Q2 2023. 7 funds tracked by Wall St. Rank hold BBLG as of Q3 2023.

  • Kepos Capital reported no remaining Bone Biologics position as of Q3 2023 after selling out during the quarter.
  • Kepos Capital sold 1,042 Bone Biologics shares in Q3 2023, an estimated $72K.
  • Kepos Capital first reported a position in Bone Biologics in Q2 2023 and held it in 1 quarter.
  • Kepos Capital's Bone Biologics position peaked at $72K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Bone Biologics as of Q3 2023.

Based on Kepos Capital's 13F filing for Q3 2023, filed 14 Nov 2023.